
CAR T Cell Therapy Research Trainee @mayoclinic - Hematology, BMT and Cell Therapy. Views are my own
Ribeirão Preto, Brasil
Joined November 2018
- Tweets44
- Following393
- Followers192
- Likes329
Larissa Brunaldi retweeted
Truly transformative data #ASH25 Very exciting time for #mmsm patients! Understanding sequence among novel immunotherapies is more important than ever! @MayoCancerCare @IMFmyeloma #IMWG Immunotherapy Committee @SurbhiSidanaMD @DrKrinaPatel Doris Hansen @MoffittNews @HiraSMian
OK here it is. Finally.
My #ASH25 algorithm for Relapsed Myeloma: First Relapse. Discussed with @YiLinMDPhD @myelomaMD
Give comments. I’m willing to adjust it based on your insights.
Larissa Brunaldi retweeted
Practical guidelines and recommendations for infection prophylaxis with CAR T and bispecific antibodies in #MultipleMyeloma from the COMMIT Consortium
onlinelibrary.wiley.com/doi/…
@MeeraMohanMD @End_myeloma @rajshekharucms @SusanBal9 @nsc_natalie @BerdejaJesus #mmsm
Larissa Brunaldi retweeted
Quick 2 read update on indications of CAR-T in blood disorders by @ASTCT Committee on practice guidelines. Great paper to reference in CAR manuscript introductions and to quote in painful peer-to-peer reviews #CART 🙏@abe_seb_kanate
pubmed.ncbi.nlm.nih.gov/3742…
Larissa Brunaldi retweeted
1/x @ASTCT Committee on Practice Guidelines releases Clinical Practice Recommendations for HCT and CAR-T in DLBCL #lymsm #bmtsm #CART
Open Access (on paywall) @ASTCT_Journal 🙏🙏🙏
astctjournal.org/article/S26…
Larissa Brunaldi retweeted
Check out abstract 1533 @ASCO #ASCO2023 for Teclistamab infusions in the outpatient setting with use of remote patient monitoring. @larissabrunaldi @YiLinMDPhD @jonaspaludo
👉23pt =155 infusions = 98% administered outpt (80% NEVER ADMITTED) ##HCSM #MedEd #mmsm #DigitalHealth
Larissa Brunaldi retweeted
#ASCO23 abstract1533 suggests that hospital-based outpatient setting is feasible and safe for administering and monitoring CAR-T #TCellRx and bispecific TCE therapies. #mmsm #lymsm @Radhika_Bansl @YiLinMDPhD @jonaspaludo mayocl.in/43mnCDn
Larissa Brunaldi retweeted
Check out abstract 1533 @ASCO #ASCO2023 for Teclistamab infusions in the outpatient setting with use of remote patient monitoring. @larissabrunaldi @YiLinMDPhD @jonaspaludo
👉23pt =155 infusions = 98% administered outpt (80% NEVER ADMITTED) ##HCSM #MedEd #mmsm #DigitalHealth
#ASCO23 abstract1533 suggests that hospital-based outpatient setting is feasible and safe for administering and monitoring CAR-T #TCellRx and bispecific TCE therapies. #mmsm #lymsm @Radhika_Bansl @YiLinMDPhD @jonaspaludo mayocl.in/43mnCDn
Larissa Brunaldi retweeted
Replying to @larissabrunaldi
@larissabrunaldi presented @MayoCancerCare experience with outpatient management of #CART & #BsAb Teclistamab: 23 patient and 155 injections given. #ASCO23
Larissa Brunaldi retweeted
Check out poster by @larissabrunaldi, visiting researcher from Brazil, presents data from @MayoCancerCare study of 161 myeloma pts treated with #CART that bone marrow and PET MRD negativity is prognostic for early relapse vs prolonged PFS #mmsm #ASCO23
Larissa Brunaldi retweeted
Replying to @Rfonsi1
Thanks for the shout-out, Dr. Fonseca! Would be great if ASCO and other meetings with large international participation would allow interpreters for more engaged Q&A. It’s another aspect of DEI for our scientific community.
Larissa Brunaldi retweeted
I heard yesterday that a presenter from China at #ASCO23 was struggling to answer questions due to language barriers, after she did an excellent presentation. Dr. @YiLinMDPhD stepped in and said: “I’m here to translate.” Well done!
Larissa Brunaldi retweeted
For #ASCO23
How I treat myeloma: a few slides.
Larissa Brunaldi retweeted
My theme, “Partnering w patients, the cornerstone of clinical care and research” builds on my career of more than 30 yrs & resonates w many of the challenges in oncology today. The theme promotes the preeminence of the relationship btwn pts & the oncology clinician #ASCO23
👉BM MRD at month one post #CART is prognostic regardless bone marrow cellularity for pts with MM rdcu.be/c9joS #mmsm @BloodCancerJnl
@Radhika_Bansl @YiLinMDPhD @Taxkourel @Rfonsi1 @myelomaMD
🤔@Radhika_Bansl What about extra medullary disease? Is there a role from PET-CT in this scenario? #ASCO2023
2
111
Larissa Brunaldi retweeted
mSMART guidelines for management of CAR-T associated cytokine release syndrome, neurotoxicity, cytopenias has just been posted. #myeloma #MedTwitter
@YiLinMDPhD @myelomaMD @MorieGertz @MayoMyeloma
msmart.org
Larissa Brunaldi retweeted
Late onset neurologic symptoms and prolonged, severe cytopenia can be particularly difficult to manage. Patients have returned home by then, care require close collaboration between #CART center and home myeloma team. #mmsm
mSMART guidelines for management of CAR-T associated cytokine release syndrome, neurotoxicity, cytopenias has just been posted. #myeloma #MedTwitter
@YiLinMDPhD @myelomaMD @MorieGertz @MayoMyeloma
msmart.org
Larissa Brunaldi retweeted
For drug approval and for clinical trial eligibility, specifying refractoriness to specific drugs/drug classes is sufficient & better than mandating number of specific lines of therapy a patient must have previously received. #MedTwitter @BloodCancerJnl nature.com/articles/s41408-0…





















